Exploration of Targeted Anti-tumor Therapy

Home
/
Exploration of Targeted Anti-tumor Therapy
/
Articles
/
T1

From: In vitro breast cancer models for studying mechanisms of resistance to endocrine therapy

Table 1

Molecular subtypes of breast cancers and treatment options outside of traditional surgery and radiotherapy [5–10]

Subtype	Molecular characteristics	Approximate incidence	Treatment options
Luminal A-like	ER⁺, PR^±, HER2^– Low Ki-67 Lower grade	60–70%	Endocrine therapy Targeted therapy Chemotherapy
Luminal B-like HER2^–	ER⁺, PR^±, HER2^– High Ki-67 Higher grade	10–20%	Endocrine therapy Targeted therapy Chemotherapy
Luminal B-like HER2⁺	ER⁺, PR^±, HER2⁺ High Ki-67 Higher grade	13–15%	Endocrine therapy Targeted therapy Chemotherapy
HER2-enriched (non-luminal)	ER^–, PR^–, HER2⁺ High Ki-67 Higher grade	13–15%	Chemotherapy Targeted therapy
Triple-negative	ER^–, PR^–, HER2^– High Ki-67 Higher grade	10–15%	Chemotherapy Targeted therapy Immunotherapy

Return to article view